 |
|
|
| |
Use of Genotypic and Maraviroc (MVC) Clinical Trial Data to Develop Statistical Models for Predicting Response in a Treatment-Naive (TN) Population
|
| |
| |
Reported by Jules Levin
ICAAC Sept 14 2010 Boston
Pinaki Biswas1, Doug Chapman1, Xiaoyin Zhong3, Guinevere Q. Lee3, P. Richard Harrigan3, Jayvant Heera2, Hernan Valdez1
1Pfizer, New York, NY; 2Pfizer, New London, CT; 3BC Centre for Excellence in HIV/AIDS, Vancouver, Canada
"Of the 320 subjects with CD4+ count >50 and g2p FPR >5.75%, 67.2%
responded"
|
| |
|
|
|
|
|
